关于SGLT2抑制剂治疗心力衰竭的全科医生观点
Lung E Teng1, Noor Lammoza1, Ar K Aung1,2
1General Medicine Unit, Alfred Health, Monash University, Melbourne, Victoria, Australia.
Internal medicine journal
|July 3, 2024
概括
一般医生熟悉用于心力衰竭 (HF) 的-葡萄糖共运输体-2 抑制剂 (SGLT2is). 然而,患者的复杂性,药物成本和护理连续性阻碍了SGLT2i的处方,影响了最佳的HF管理.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 一般医学 一般医学.
背景情况:
- -葡萄糖携带载体-2 抑制剂 (SGLT2is) 是对心力衰竭 (HF) 的新兴治疗方法.
- 现在的指导方针建议SGLT2is用于高频管理.
- 了解全科医生 (GPs) 的观点是优化SGLT2i使用的关键.
研究的目的:
- 调查全科医生在开处方SGLT2is时面临的临床问题和障碍.
- 评估一般医生对SGLT2i在一般医学环境中的使用的看法.
主要方法:
- 一份问卷调查分发给澳大利亚和新西兰内部医学协会的成员.
- 该调查探讨了全科医生的经验,舒适度和关于给HF患者处方SGLT2i的障碍.
- 包括两个临床场景来衡量实际应用.
主要成果:
- 低响应率 (10.8%) 产生了98名参与者,主要是大都会公共医院的高级工作人员.
- 对SGLT2的处方率有所不同:对于减少喷射分数的HF,23%的处方率频繁,对于保留喷射分数的HF,57.1%的处方率不到25%.
- 虽然对SGLT2i疗法 (44%) 和副作用 (47%) 的熟悉度很高,但主要障碍包括患者的复杂性,药物成本和护理中断. 优糖性糖尿病酸性脂肪酸症是48%的人的主要担忧.
结论:
- 澳大利亚和新西兰的全科医生对SGLT2i治疗和潜在的副作用有很好的了解.
- 对SGLT2i采用HF的重大障碍包括患者相关因素,药物费用和分散的医疗保健服务.
- 解决这些障碍对于改善SGLT2i在HF初级护理中的实施至关重要.
相关概念视频
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
187
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
187
01:23Dipeptidyl Peptidase 4 Inhibitors
180
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
180
01:26Heart Failure Drugs: Inotropic Agents
564
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
564
01:22Heart Failure Drugs: Diuretics
362
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
362
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
419
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
419
01:27Glucose Transporters
22.6K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
22.6K